Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer

Cancer

Volumn 112, Issue 11, 2008, Pages 2467-2474

  Ye, Yuanqing ^a   Yang, Hushan ^a   Barton Grossman, H ^a   Dinney, Colin ^a   Wu, Xifeng ^a   Gu, Jian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; CART; Cell cycle control pathway; Gene gene interaction; Risk assessment; SNP

Indexed keywords

AURORA A KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN P21; PROTEIN P27; PROTEIN P53; CELL CYCLE PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE REGULATION; DEMOGRAPHY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HUMAN; INTERVIEW; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; CASE CONTROL STUDY; CELL CYCLE; COMPARATIVE STUDY; GENE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; CELL CYCLE; CELL CYCLE PROTEINS; FEMALE; GENES, CDC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS; VARIATION (GENETICS);

EID: 52049108964     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23472     Document Type: Article

References (34)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Detailed Guide: Bladder Cancer, What Are the Risk Factors for Bladder Cancer? Atlanta, GA: American Cancer Society.
3. Wu X, Lin J, Grossman HB, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007;25:4974-4981.
4. Carreon T, LeMasters GK, Ruder AM, Schulte PA. The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers. Front Biosci. 2006;11:2889-2902.
5. Terry PD, Umbach DM, Taylor JA. APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. Int J Cancer. 2006;118:3170-3173.
6. Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front Biosci. 2007;12:192-213.
7. Andrew AS, Nelson HH, Kelsey KT, et al. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis. 2006;27:1030-1037.
8. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:939-943.
9. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A. 1997;94:2776-2778.
10. Doherty SC, McKeown SR, McKelvey-Martin V, et al. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst. 2003;95:1859-1868.
11. Ford HL, Pardee AB. Cancer and the cell cycle. J Cell Biochem. 1999;33(Suppl 32):166-172.
12. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681-690.
13. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
14. Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer; 1999.
15. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954-1956.
16. Wang-Gohrke S, Chang-Claude J. Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany. Breast Cancer Res Treat. 2004;88:231-237.
17. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J. 2004;25:1568-1573.
18. Biro E, Kalina I, Salagovic J, Habalova V, Hriv AK, Valansky ML. p53 single nucleotide polymorphisms and bladder cancer. Neoplasma. 2000;47:303-306.
19. Chen WC, Wu HC, Hsu CD, Chen HY, Tsai FJ. p21 gene codon 31 polymorphism is associated with bladder cancer. Urol Oncol. 2002;7:63-66.
20. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A casecontrol study of cyclin D1 CCND1 870A- > G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645-1650.
21. Mabrouk I, Baccouche S, El-Abed R, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003;1010:764-770.
22. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179:175-183.
23. Toruner GA, Ucar A, Tez M, Cetinkaya M, Ozen H, Ozcelik T. P53 codon 72 polymorphism in bladder cancer - no evidence of association with increased risk or invasiveness. Urol Res. 2001;29:393-395.
24. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257-264.
25. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2006;98:1014-1018.
26. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 2002.
27. Knudsen KE. The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div. 2006;1:15.
28. Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis. 2004;9:797-805.
29. Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood. 2002;99:4554-4561.
30. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744-1750.
31. Nadal A, Jares P, Pinyol M, et al. Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. Virchows Arch. 2007;450:161-167.
32. Takano Y, Takenaka H, Kato Y, et al. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res. Clin Oncol. 1999;125:505-512.
33. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene. 1994;9:2663-2674.
34. Wright ME, Mayne ST, Stolzenberg-Solomon RZ, et al. Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers. Am J Epidemiol. 2004;160:68-76.